• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Amarin Corp ADR (NQ: AMRN )

    0.6047 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Amarin Corp ADR

    < Previous 1 2
    ...
    4 5 6 7 8 9 10 11 Next >
    Amarin Corp: Q2 Earnings Insights
      Amarin Corp (NASDAQ:AMRN) reported its Q2 earnings results on Wednesday, August 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
    Via Benzinga
    Why Is Akebia Therapeutics Surging By 28%? 48 Stocks Moving In Friday's Mid-Day Session
    Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) rose 56.1% to $ 0.7029 after dropping 10% on Thursday. 
    Via Benzinga
    Sarissa Capital Intends to Vote “Abstain” at the Amarin Annual Meeting
    From Sarissa Capital Management LP
    Via Business Wire
    Amarin Outlines $100M Cost Saving Plan
    Via Benzinga
    Recap: Amarin Corp Q1 Earnings
    Amarin Corp (NASDAQ:AMRN) reported its Q1 earnings results on Wednesday, May 4, 2022 at 06:00 AM. Here's what investors need to know about the announcement. 
    Via Benzinga
    Earnings Scheduled For March 1, 2022
    Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated... 
    Via Benzinga
    Akerna Shares Dip 53%, Here's 78 Biggest Movers From Yesterday
    Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) surged 77.4% to close at $1.11 on Thursday after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase... 
    Via Benzinga
    Looking Into Amarin Corp's Return On Capital Employed
    Amarin Corp (NASDAQ:AMRN) brought in sales totaling $94.63 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 314.74%, resulting in a loss of $31.56 million. 
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For May 6, 2022
    Upgrades For Coupang Inc (NYSE:CPNG), JP Morgan upgraded the previous rating of Neutral to Overweight. The stock has a 52-week-high of $46.00 and a 52-week-low of $11.91. At the end of the last trading... 
    Via Benzinga
    A Peek Into The Markets: US Stock Futures Down; Jobs Report In Focus
    Pre-open movers 
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2022
    Upgrades 
    Via Benzinga
    10 Biggest Price Target Changes For Thursday
    Needham cut Cirrus Logic, Inc. (NASDAQ: CRUS) price target from $110 to $100. Cirrus Logic shares rose 4.5% to close at $82.81 on Wednesday. 
    Via Benzinga
    81 Biggest Movers From Yesterday
    Gainers Rail Vision Ltd. (NASDAQ: RVSN) shares climbed 62.4% to close at $2.16 on Wednesday after gaining around 5% on Tuesday. 
    Via Benzinga
    Mid-Afternoon Market Update: Crude Oil Jumps 5%; Fed Boosts Interest Rates By 0.5%
    U.S. stocks traded mixed toward the end of trading, after the Federal Reserve announced its policy decision. 
    Via Benzinga
    50 Stocks Moving In Wednesday's Mid-Day Session
    Gainers Rail Vision Ltd. (NASDAQ: RVSN) shares jumped 51.7% to $2.0180 after gaining around 5% on Tuesday. Sharps Technology, Inc. (NASDAQ: STSS) rose 31.4% to $1.6815 after... 
    Via Benzinga
    Mid-Day Market Update: Dow Rises 100 Points; Lyft Shares Plummet
    U.S. stocks traded mixed midway through trading, with the Dow Jones gaining more than 100 points on Wednesday. 
    Via Benzinga
    Mid-Morning Market Update: Markets Mixed; Nasdaq Tumbles 100 Points
    U.S. stocks traded mixed this morning, with the Nasdaq dropping more than 100 points on Wednesday. 
    Via Benzinga
    The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
    Here's a roundup of top developments in the biotech space over the last 24 hours. 
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    Amarin Corp's Earnings: A Preview
    Amarin Corp (NASDAQ:AMRN) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that Amarin Corp... 
    Via Benzinga
    The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
    Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks... 
    Via Benzinga
    NASDAQ:AMRN Long Term Investor Notice: Investigation of Potential Wrongdoing at Amarin Corporation Plc
    San Diego, CA -- (SBWIRE) -- 03/09/2022 -- An investigation was announced for investors in shares of Amarin Corporation plc (NASDAQ:AMRN) concerning potential breaches of fiduciary duties by certain... 
    Via SBWire
    The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
    Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine... 
    Via Benzinga
    Lower Vascepa Volume Hits Amarin's Q4 Topline Growth
    Amarin Corp plc's (NASDAQ: AMRN) Q4 FY21 sales decreased 13.6% Y/Y to $144.49 million, beating the consensus of $141.75 million. The decline was driven primarily by... 
    Via Benzinga
    Amarin: Q4 Earnings Insights
    Amarin Corp (NASDAQ:AMRN) reported its Q4 earnings results on Tuesday, March 1, 2022 at 06:00 AM. Here's what investors need to know about the announcement. Earnings... 
    Via Benzinga
    The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
    Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first... 
    Via Benzinga
    28 Stocks Moving In Tuesday's Mid-Day Session
    Gainers Sierra Oncology, Inc. (NASDAQ: SRRA) shares jumped 47.8% to $22.93 after the company unveiled topline data for momelotinib in myelofibrosis patients who are symptomatic,... 
    Via Benzinga
    51 Biggest Movers From Yesterday
    Gainers Sierra Oncology, Inc. (NASDAQ: SRRA) shares climbed 46.2% to close at $22.68 on Tuesday after the company unveiled topline data for momelotinib in myelofibrosis patients... 
    Via Benzinga
    The Daily Biotech Pulse: Pfizer-BioNTech Starts Omicron-Specific Vaccine Study, J&J Misses On Topline, Sierra Oncology Reports Positive Data
    Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Pfizer, BioNTech Initiates Study Of Omicron-Based Vaccine Candidate Pfizer,... 
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    Good morning, investor! We're starting off the day right with a dive into the biggest pre-market stock movers for Tuesday! 
    Via InvestorPlace
    < Previous 1 2
    ...
    4 5 6 7 8 9 10 11 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.